JP2018505861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505861A5 JP2018505861A5 JP2017533018A JP2017533018A JP2018505861A5 JP 2018505861 A5 JP2018505861 A5 JP 2018505861A5 JP 2017533018 A JP2017533018 A JP 2017533018A JP 2017533018 A JP2017533018 A JP 2017533018A JP 2018505861 A5 JP2018505861 A5 JP 2018505861A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- terminal
- terminal peptide
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 101800001415 Bri23 peptide Proteins 0.000 claims 7
- 101800000655 C-terminal peptide Proteins 0.000 claims 7
- 102400000107 C-terminal peptide Human genes 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 108010040721 Flagellin Proteins 0.000 claims 3
- 101800000597 N-terminal peptide Proteins 0.000 claims 3
- 102400000108 N-terminal peptide Human genes 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 206010042566 Superinfection Diseases 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims 1
- 108010044267 Abnormal Hemoglobins Proteins 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 108010015899 Glycopeptides Proteins 0.000 claims 1
- 102000002068 Glycopeptides Human genes 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 108010028921 Lipopeptides Proteins 0.000 claims 1
- 241000588655 Moraxella catarrhalis Species 0.000 claims 1
- 108010040201 Polymyxins Proteins 0.000 claims 1
- 229930189077 Rifamycin Natural products 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 108010034396 Streptogramins Proteins 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims 1
- 229960003022 amoxicillin Drugs 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 229940124307 fluoroquinolone Drugs 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims 1
- 229940041153 polymyxins Drugs 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 claims 1
- 229940081192 rifamycins Drugs 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 229940041030 streptogramins Drugs 0.000 claims 1
- 229940006995 sulfamethoxazole and trimethoprim Drugs 0.000 claims 1
- -1 sulfamethoxazoles Substances 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229940040944 tetracyclines Drugs 0.000 claims 1
- 150000003952 β-lactams Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14307154.6 | 2014-12-23 | ||
| EP14307154 | 2014-12-23 | ||
| PCT/EP2015/080924 WO2016102536A1 (en) | 2014-12-23 | 2015-12-22 | Methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020033407A Division JP2020138968A (ja) | 2014-12-23 | 2020-02-28 | インフルエンザ後の細菌重感染を処置するための方法及び医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505861A JP2018505861A (ja) | 2018-03-01 |
| JP2018505861A5 true JP2018505861A5 (OSRAM) | 2018-10-25 |
| JP6912379B2 JP6912379B2 (ja) | 2021-08-04 |
Family
ID=52432622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533018A Active JP6912379B2 (ja) | 2014-12-23 | 2015-12-22 | インフルエンザ後の細菌重感染を処置するための方法及び医薬組成物 |
| JP2020033407A Pending JP2020138968A (ja) | 2014-12-23 | 2020-02-28 | インフルエンザ後の細菌重感染を処置するための方法及び医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020033407A Pending JP2020138968A (ja) | 2014-12-23 | 2020-02-28 | インフルエンザ後の細菌重感染を処置するための方法及び医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10736937B2 (OSRAM) |
| EP (1) | EP3236988B8 (OSRAM) |
| JP (2) | JP6912379B2 (OSRAM) |
| ES (1) | ES2809598T3 (OSRAM) |
| WO (1) | WO2016102536A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3781200B1 (en) * | 2018-04-16 | 2024-05-29 | F. Hoffmann-La Roche AG | Antibodies for chelated radionuclides |
| FR3114970B1 (fr) | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| US20240277801A1 (en) | 2021-06-30 | 2024-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Aerosol composition for pulmonary delivery of flagellin |
| WO2025172452A1 (en) | 2024-02-14 | 2025-08-21 | Institut National de la Santé et de la Recherche Médicale | Combination for treating bacterial infection due to pseudomonas aeruginosa antibiotic-resistant strain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2695941B1 (en) * | 2008-06-25 | 2015-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel immunoadjuvant flagellin-based compounds and use thereof |
| JP5746761B2 (ja) * | 2010-06-25 | 2015-07-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 気道感染症の処置のための方法及び医薬組成物 |
| US20150224129A1 (en) * | 2012-10-03 | 2015-08-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists |
| WO2014053481A1 (en) * | 2012-10-03 | 2014-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza |
| JP6274904B2 (ja) * | 2014-02-25 | 2018-02-07 | キヤノン株式会社 | 固体撮像装置及び撮像システム |
-
2015
- 2015-12-22 EP EP15817338.5A patent/EP3236988B8/en active Active
- 2015-12-22 WO PCT/EP2015/080924 patent/WO2016102536A1/en not_active Ceased
- 2015-12-22 ES ES15817338T patent/ES2809598T3/es active Active
- 2015-12-22 US US15/537,596 patent/US10736937B2/en active Active
- 2015-12-22 JP JP2017533018A patent/JP6912379B2/ja active Active
-
2020
- 2020-02-28 JP JP2020033407A patent/JP2020138968A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2271468T3 (es) | Nuevas indicaciones de la lecitina de union a manano (mbl) en el tratamiento de individuos inmunocomprometidos. | |
| JP2018511327A5 (OSRAM) | ||
| JP2018505861A5 (OSRAM) | ||
| JP2006507270A5 (OSRAM) | ||
| HRP20160274T1 (hr) | Pripravci i metode vezane za varijante proteina a (spa) | |
| JP2015522576A5 (OSRAM) | ||
| JP2015517489A5 (OSRAM) | ||
| JP2016074740A5 (OSRAM) | ||
| JP2012522808A5 (OSRAM) | ||
| JP2013534532A5 (OSRAM) | ||
| JPWO2019156137A5 (OSRAM) | ||
| IL262805B2 (en) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death | |
| JP2019533722A5 (OSRAM) | ||
| JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| JP2016529229A5 (OSRAM) | ||
| JP2017526627A5 (OSRAM) | ||
| HRP20161458T1 (hr) | Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze | |
| JP2017505772A5 (OSRAM) | ||
| CN110799522A (zh) | 用于治疗、改善或预防脑出血的肽及其用途 | |
| JP2017536124A5 (OSRAM) | ||
| JP2017514895A5 (OSRAM) | ||
| JP2016515123A5 (OSRAM) | ||
| RU2016135003A (ru) | Новые виды лечения | |
| JP2025041746A5 (OSRAM) | ||
| JP2015515280A5 (OSRAM) |